At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 49 enrolled
Drug / intervention
everolimus +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of the mTOR Inhibitor RAD001 in Previously Treated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Stomach
Translational Oncology Research International·interventional·Posted Sep 28, 2009·Updated Aug 5, 2020
In Brief
A Phase 2 clinical trial evaluating everolimus and laboratory biomarker analysis for Esophageal Cancer and Gastric Cancer. Completed, enrolled 49 participants across 18 sites.
Detailed Summary
RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well everolimus works in treating patients with previously treated unresectable or metastatic esophageal cancer or stomach cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEsophageal Cancer, Gastric Cancer
CountriesUnited States
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartSep 2009
First PostedSep 2009
Primary CompletionMay 2014
TodayJul 2026
First PostedSep 28, 2009
Enrollment StartSep 1, 2009
Primary CompletionMay 1, 2014
TodayJul 2, 2026
Enrollment to primary: 4.7 yearsPosted 16.8 years ago
Interventions
everolimusdrug
laboratory biomarker analysisother